The review found no eligible studies for this question.
HALOPERIDOL leads to lower specific behaviours ‐ threat or injury to others/self compared with OTHER ANTIPSYCHOTICS (high certainty).
The review found no eligible studies for this question.
HALOPERIDOL leads to lower global outcomes ‐ overall improvement compared with OTHER ANTIPSYCHOTICS (high certainty).
HALOPERIDOL showed no clear difference in leaving the study early compared with OTHER ANTIPSYCHOTICS (low certainty).
The review found no eligible studies for this question.
Haloperidol showed no clear difference in clinically important response to treatment (short term) compared with first‐generation antipsychotics (low certainty).
It is very uncertain whether haloperidol changes adverse effects: number of participants with at least one adverse… compared with first‐generation antipsychotics (very low certainty).
It is very uncertain whether haloperidol changes adverse effects: extrapyramidal side effects: number of participants… compared with first‐generation antipsychotics (very low certainty).
Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).
It is very uncertain whether haloperidol changes leaving the study early due to inefficacy of treatment as a measure… compared with first‐generation antipsychotics (very low certainty).
It is very uncertain whether haloperidol changes leaving the study early due to adverse events as a measure of… compared with first‐generation antipsychotics (very low certainty).
Haloperidol showed no clear difference in adverse effects: number of participants with at least one adverse… compared with first‐generation antipsychotics (low certainty).
It is very uncertain whether haloperidol changes adverse effects: extrapyramidal side effects: number of participants… compared with first‐generation antipsychotics (very low certainty).
Haloperidol may leads to lower clinically important response to treatment (medium term) compared with first‐generation antipsychotics (low certainty).
It is very uncertain whether haloperidol changes leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (very low certainty).
HALOPERIDOL showed no clear difference in clinical response to treatment compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
HALOPERIDOL showed no clear difference in leaving the study early ‐ Due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
It is very uncertain whether HALOPERIDOL changes adverse effects ‐ at least one adverse effect compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).